SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 5A4460) has been filed by Ecolab Inc., 370 North Wabasha St., St. Paul, MN 55102. The petition proposes to amend the food additive regulation in § 173.315 *Chemicals used in washing or to assist in the lye peeling of fruits and vegetables* (21 CFR 173.315) to provide for the safe use of a mixture of peroxyacetic acid, acetic acid, hydrogen peroxide, and 1-hydroxyethylidene-1,1-diphosphonic acid to control microbial growth in water contacting fruits and vegetables.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may on or before August 14, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: July 3, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–17235 Filed 7–12–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95G–0156]

Sandoz Nutrition Corp.; Filing of Petition for Affirmation of GRAS Status

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Sandoz Nutrition Corp. has filed a petition (GRASP 5G0414), proposing to affirm that partially hydrolyzed guar gum (PHGG) is generally recognized as safe (GRAS) as an ingredient in human food.

DATES: Written comments by September 26, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Rosalie M. Angeles, Center for Food Safety and Applied Nutrition (HFS–207), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3107.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (secs. 201(s) and 409(b)(5) (21 U.S.C. 321(s) and 348(b)(5)) and the regulations for affirmation of GRAS status in § 170.35 (21 CFR 170.35), notice is given that Sandoz Nutrition Corp., 5320 West Twenty Third St., P.O. Box 370, Minneapolis, MN 55440, has filed a petition (GRASP 5G0414), proposing that PHGG be affirmed as GRAS for use in human food. The petition has been placed on display at the Dockets Management Branch (address above).

Any petition that meets the requirements outlined in § 170.30 (21 CFR 170.30) and § 170.35 is filed by the agency. There is no prefiling review of the adequacy of data to support a GRAS conclusion. Thus, the filing of a petition for GRAS affirmation should not be interpreted as a preliminary indication of the suitability for GRAS affirmation.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Interested persons may, on or before September 26, 1995, review the petition and/or file comments (two copies of any comments should be filed and should be identified with the docket number found in brackets in the heading of this document) with the Dockets Management Branch (address above). Comments should include any available information that would be helpful in determining whether the substance is, or is not, GRAS for the proposed use. In addition, consistent with the regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b), the agency encourages public participation by review of and comment on the environmental assessment submitted with the petition that is the subject of this notice. A copy of the petition (including the environmental assessment) and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: June 23, 1995.

Alan M. Rulis,

Acting Dirctor, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–17233 Filed 7–12–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 95N–0202]

Drug Export; Preservative-Free Intravenous Sodium Edecrin® (Ethacrynate Sodium) 50 Milligrams (mg) Ethacrynic Acid Equivalent/50 Milliliters (mL) in 60 mL Glass Bottle

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Merck & Co. has filed an application requesting approval for the export of the human drug Preservative-Free Intravenous Sodium Edecrin® (ethacrynate sodium) 50 mg ethacrynic acid equivalent/50 mL in 60 mL glass bottle to Germany through the Netherlands for further packaging and labeling.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Center for Drug Evaluation and Research (HFD–310), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, 301–594–3150.